Tradestie Institutional Equity Comparison Engine

CRCA vs CWVX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRCA Overall Edge

CRCA Captures Institutional Edge (1โ€“0 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ProShares Ultra CRCL (CRCA) driven by superior Momentum & Technical. Fundamentally, CRCA trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CWVX at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, CRCA sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against CWVX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CRCA N/M vs CWVX N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner CRCA
1Y +61.0% vs -33.5% ยท 52W Pos 7% vs 2%
Options & Structure Winner Tie
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (<1st %ile IV)
CRCA NYSE Arca
ProShares Ultra CRCL
Institutional Equity
$7.84
-14.5% 1D
Market Cap N/A
1M Return -53.61%
1Y Return +60.99%
Forward P/E N/M
Unified AI Score
51.0 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 50.0 Mom 60.0
CWVX Cboe BZX
Tradr 2X Long CRWV Daily ETF
Institutional Equity
$3.98
-12.14% 1D
Market Cap N/A
1M Return -43.14%
1Y Return -33.5%
Forward P/E N/M
Unified AI Score
54.6 / 100 HOLD
Tech 65.0 Fund 58.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRCA +60.99% CWVX -33.5% Spread: +94.49 pp (CRCA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRCA TTM Op. Margin: N/A CWVX TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRCA vs CWVX. Trailing 12-month operating profitability (CRCA N/A vs CWVX N/A) and valuation multiples (CRCA N/M vs CWVX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRCA (2) vs CWVX (1)
Institutional Metric CRCA CWVX Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 7% ($1โ€“$93) 2% ($3โ€“$57) Stronger Trend CRCA
Beta / 30D Volatility Risk Regime 4.88ฮฒ ยท 137% Vol 6.65ฮฒ ยท 271% Vol Lower Realized Risk CRCA
Unified Institutional Score Composite Signal 51.0 / 100 (HOLD) 54.6 / 100 (HOLD) Higher Composite CWVX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRCA vs CWVX Buy Guide
CRCA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live CRCA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CWVX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live CWVX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRCA nor CWVX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.